Velcade "Impressive" Efficacy Offsets Concern Over Response As Endpoint
This article was originally published in The Pink Sheet Daily
Executive SummaryMillennium’s multiple myeloma agent response rate is "better than expected," NDA review documents indicate. FDA reverses its initial request for Phase III study results to support accelerated approval after final data from Phase II are submitted.
You may also be interested in...
Hours before the US FDA confirmed the first drug shortage due to active pharmaceutical ingredient constraints because of the coronavirus situation in China, generics industry leader Mylan came under pressure about the potential impact on its business.